Therefore, upregulation of ligands for inhibitory NK receptors that express ITIMs by cancer cells, such as HLA-E and PD-L1, may repress NK cell activity through SHP-1 recruitment and activity (Carretero et al., 1998; Chemnitz et al., 2004). This evidence concerns the gene NR0B2 and cancer.